Q-omics provides the consensus-scored MIR421 profile across patient tissues and cancer cell-line models. MIR421 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MIR421 is differentially expressed in 8, with the highest sampling consensus in BRCA. Additionally, MIR421 RNA expression shows 17,466 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, BRCA, and TGCT as cancer lineages where MIR421 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR421 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR421 survival associations across molecular data types. MIR421 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR421 RNA expression–survival associations across cancer types. High MIR421 expression shows unfavorable associations in COAD and UVM, but favorable associations in ACC, CHOL, SKCM and UCS. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MIR421 RNA expression.
This table summarizes MIR421 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR421. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR421 shows lower tumor expression in BRCA, THCA, LUAD and LUSC and higher tumor expression in HNSC and CHOL. The BRCA box plot shows higher MIR421 RNA expression in normal versus tumor tissue (log2 FC = −1.046, t-test p < 0.001).
This table shows molecular features associated with MIR421 in patient tissues and cancer cell lines. In patient samples, MIR421 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
